Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
PlantPraxis Biotecnologia is a Brazil-based joint venture using PlantForm’s vivoXPRESS plant-based expression system to develop and manufacture biosimilar monoclonal antibodies, including a biosimilar adalimumab for rheumatoid arthritis and other inflammatory disorders and a biosimilar pembrolizumab for multiple cancers; public information describes R&D collaboration and facility construction, with development expected to lead to Phase 1 and Phase 3 clinical trials but no completed clinical trial results reported yet.[1][4][5]
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on PlantPraxis Biotecnologia.